These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32352753)

  • 1. Dual Neutral Sphingomyelinase-2/Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease.
    Bilousova T; Simmons BJ; Knapp RR; Elias CJ; Campagna J; Melnik M; Chandra S; Focht S; Zhu C; Vadivel K; Jagodzinska B; Cohn W; Spilman P; Gylys KH; Garg NK; John V
    ACS Chem Biol; 2020 Jun; 15(6):1671-1684. PubMed ID: 32352753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer's Disease.
    Šála M; Hollinger KR; Thomas AG; Dash RP; Tallon C; Veeravalli V; Lovell L; Kögler M; Hřebabecký H; Procházková E; Nešuta O; Donoghue A; Lam J; Rais R; Rojas C; Slusher BS; Nencka R
    J Med Chem; 2020 Jun; 63(11):6028-6056. PubMed ID: 32298582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease.
    Hu J; Huang YD; Pan T; Zhang T; Su T; Li X; Luo HB; Huang L
    ACS Chem Neurosci; 2019 Jan; 10(1):537-551. PubMed ID: 30252439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
    McHardy SF; Wang HL; McCowen SV; Valdez MC
    Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease.
    Hu XM; Dong W; Cui ZW; Gao CZ; Yu ZJ; Yuan Q; Min ZL
    J Mol Model; 2018 Jun; 24(7):151. PubMed ID: 29869722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer's Disease.
    Kumar B; Dwivedi AR; Sarkar B; Gupta SK; Krishnamurthy S; Mantha AK; Parkash J; Kumar V
    ACS Chem Neurosci; 2019 Jan; 10(1):252-265. PubMed ID: 30296051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
    Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM
    Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.
    Zhou LY; Zhu Y; Jiang YR; Zhao XJ; Guo D
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4180-4184. PubMed ID: 28751142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer's disease.
    Manzoor S; Gabr MT; Rasool B; Pal K; Hoda N
    Bioorg Chem; 2021 Nov; 116():105354. PubMed ID: 34562674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease.
    Iman K; Mirza MU; Mazhar N; Vanmeert M; Irshad I; Kamal MA
    CNS Neurol Disord Drug Targets; 2018 Apr; 17(1):54-68. PubMed ID: 29336270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents.
    Galdeano C; Viayna E; Arroyo P; Bidon-Chanal A; Blas JR; Muñoz-Torrero D; Luque FJ
    Curr Pharm Des; 2010; 16(25):2818-36. PubMed ID: 20698824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents.
    Ambure P; Kar S; Roy K
    Biosystems; 2014 Feb; 116():10-20. PubMed ID: 24325852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.
    Bowroju SK; Penthala NR; Lakkaniga NR; Balasubramaniam M; Ayyadevara S; Shmookler Reis RJ; Crooks PA
    Bioorg Med Chem; 2021 Sep; 45():116311. PubMed ID: 34304133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
    Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
    ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2.
    Bilousova T; Elias C; Miyoshi E; Alam MP; Zhu C; Campagna J; Vadivel K; Jagodzinska B; Gylys KH; John V
    Biochem Biophys Res Commun; 2018 May; 499(4):751-757. PubMed ID: 29604274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of hydrazones as dual inhibitors of ryanodine receptors and acetylcholinesterases for Alzheimer's disease.
    Yang F; Zhao J; Chen G; Han H; Hu S; Wang N; Wang J; Chen Y; Zhou Z; Dai B; Hou Y; Liu Y
    Bioorg Chem; 2023 Apr; 133():106432. PubMed ID: 36841050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase.
    Sun Q; Peng DY; Yang SG; Zhu XL; Yang WC; Yang GF
    Bioorg Med Chem; 2014 Sep; 22(17):4784-91. PubMed ID: 25088549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine.
    Jiang X; Liu C; Zou M; Xie H; Lin T; Lyu W; Xu J; Li Y; Feng F; Sun H; Liu W
    Eur J Med Chem; 2021 Nov; 223():113663. PubMed ID: 34198150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties.
    Figuera-Losada M; Stathis M; Dorskind JM; Thomas AG; Bandaru VV; Yoo SW; Westwood NJ; Rogers GW; McArthur JC; Haughey NJ; Slusher BS; Rojas C
    PLoS One; 2015; 10(5):e0124481. PubMed ID: 26010541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease.
    Li Y; Zhang XX; Jiang LJ; Yuan L; Cao TT; Li X; Dong L; Li Y; Yin SF
    Chem Biol Drug Des; 2015 Oct; 86(4):776-82. PubMed ID: 25736722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.